XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Trade Receivables
 3 Months Ended
Mar. 31, 2023
Receivables [Abstract]  
Trade Receivables Trade Receivables
Product Sales
Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and RAPIVAB. At March 31, 2023 and December 31, 2022, receivables related to sales of ORLADEYO were $47,403 and $41,508, respectively. At March 31, 2023 and December 31, 2022, receivables related to sales of RAPIVAB were $145 and $823, respectively. No reserve or allowance amounts were recorded as of March 31, 2023 and December 31, 2022.
Collaborations
Receivables from collaborations were as follows (in thousands):
March 31, 2023
BilledUnbilledTotal
U.S. Department of Health and Human Services, net$286 $284 $570 
Royalty receivables from partners521 — 521 
Total receivables$807 $284 $1,091 
December 31, 2022
BilledUnbilledTotal
U.S. Department of Health and Human Services, net$7,218 $284 $7,502 
Royalty receivables from partners741 — 741 
Other collaborations— 25 25 
Total receivables$7,959 $309 $8,268 
As of both March 31, 2023 and December 31, 2022, the Company maintained a reserve of $437 related to royalties associated with Green Cross.